Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hsp70-derived peptide vaccine
- Development stage
- Unknown
- Lead developer
- Mie University
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The HSP70-derived peptide vaccine is a cancer immunotherapy consisting of a peptide fragment derived from Heat Shock Protein 70 (HSP70). HSP70 is a molecular chaperone that is frequently overexpressed in various solid tumors, where it contributes to protein stability and tumor cell survival. The vaccine is designed to stimulate the patient's immune system, specifically inducing a cytotoxic T lymphocyte (CTL) response against tumor cells that present HSP70-derived epitopes on their surface. In clinical development, notably in the Phase I trial jRCTs061180058 in Japan, it is evaluated in combination with other agents such as GPC3-derived peptides, the LAG-3Ig fusion protein IMP321, and the TLR3 agonist Hiltonol (poly-ICLC) to enhance the overall antitumor immune response in patients with advanced or metastatic gastrointestinal and other solid cancers.
- Other names
- HSP70-derived peptide vaccineHSP-70-derived peptide vaccineHSP 70-derived peptide vaccineHeat shock protein 70-derived peptide vaccine
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)LRP1 (Prolow-density lipoprotein receptor-related protein 1)
Beyond the preview
Go deeper on hsp70-derived peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hsp70-derived peptide vaccine.